Fewer Major Bleeds With Once-Daily Enoxaparin for VTE
On propensity analysis, patients on enoxaparin once daily had fewer major bleeds and deaths at 15 and at 30 days than those on enoxaparin twice daily.
(HealthDay News) — Once-daily enoxaparin is associated with fewer major bleeds than enoxaparin twice daily in patients with acute venous thromboembolism (VTE), according to a study published online in the Journal of Thrombosis and Haemostasis.
Javier Trujillo-Santos, MD, PhD, from the Hospital General Universitario Santa Lucía in Murcia, Spain, and colleagues assessed data from the RIETE registry for 4730 patients receiving enoxaparin: 3786 and 944 received enoxaparin twice and once daily, respectively.
The researchers found that, compared with those receiving enoxaparin twice daily, once-daily enoxaparin correlated with a trend toward more VTE recurrences (odds ratio [OR], 1.79; 95% confidence interval [CI], 0.55 to 5.88), fewer major bleeds (OR, 0.42; 95% CI, 0.17 to 1.08), and fewer deaths (OR, 0.32; 95% CI, 0.13 to 0.78) during the first 15 days. Patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95% CI, 1.03 to 5.88), fewer major bleeds (OR, 0.40; 95% CI, 0.17 to 0.94), and fewer deaths (OR, 0.58; 95% CI, 0.33 to 1.00) at day 30. On propensity analysis, patients on enoxaparin once daily had fewer bleeds at 15 and 30 days (hazard ratios, 0.30 [95% CI, 0.10 to 0.88] and 0.16 [95% CI, 0.04 to 0.68]) and fewer deaths at 15 and 30 days (hazard ratios, 0.37 [95% CI, 0.14 to 0.99] and 0.19 [95% CI, 0.07 to 0.54]).
"Enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily," the authors write.
The RIETE registry was supported by Sanofi Spain and Bayer Pharma AG.
- Trujillo-Santos J, Bergmann JF, Cristiano B, et al. Once- versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. J Thromb Haemost. 25 January 2017. doi: 10.1111/jth.13616